◐ Forecasted · FOR-FD-25-004
Center for Research on Complex Generics (U18) Clinical Trials Optional
Food and Drug Administration · HHS
CFDA Numbers
93.103
Award Ceiling
$1.5M
Award Floor
$1.5M
Expected Awards
1
Close Date
—
Section I
How to Apply
Program Contact
terrin.brown@fda.hhs.gov
2404027610
Section II
Eligibility
Eligible Applicant Types
00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 99
Section III
Description
The Food and Drug Administration (FDA) seeks to fund a Center for Research on Complex Generics under the terms and conditions of a cooperative agreement. The Center for Research on Complex Generics will support the FDA's efforts to enhance collaborations with the generic drug industry relating to generic drug research, to further the FDA's mission of increasing patient access to high quality, safe, and effective generic drugs.The goals of a Center for Research on Complex Generics include: 1) Facilitating engagement with generic industry representatives to help identify scientific challenges for generic product development or assessment, and helping to inform FDA about priority areas for research to address these challenges by supporting engagement and coordination between the FDA and key generic industry industry associations, companies, and representatives.2) Providing a forum for experts from FDA, academia, the generic drug industry, and elsewhere to collaborate on research related to generic products.3) Coordinating and conducting research projects pertaining to generic products, particularly complex generics.4) Hosting scientific workshops, providing training, and supporting other educational activities pertaining to generic drug research.5) Providing free and open public access to generic drug research outcomes such as scientific articles, posters, presentations, and other resources that help the generic drug industry to leverage scientific insights from FDA funded generic drug research.The Center for Research on Complex Generics is expected to complement FDA's existing regulatory science programs through its specific focus as a hub for coordination and engagement between FDA and the public, including academic experts, generic industry representatives, and other stakeholders.